title: Investigation of intratumoural and peritumoural lymphatics expressed by podoplanin and LYVE-1 in the hybridoma-induced tumours.
abstract: Tumour-associated lymphatics contribute to a key component of metastatic spread, however, the biological interaction of tumour cells with intratumoural and peritumoural lymphatics (ITLs and PTLs) has remained unclear. To address this important issue, we have focused on the morphological and molecular aspects of newly formed lymphatics (lymphangiogenesis) and pre-existing lymphatics in the intratumoural and peritumoural tissues by using a hybridoma-induced tumour model. In the present study, ITLs with very high vessel density within the tumour mass showed small and flattened contours that varied from non-solid-to-solid tumours, whereas PTLs were relatively disorganized and tortuous, and packed with a cluster of tumour cells at the tumour periphery. Lymphatic endothelial cells (LECs) both in ITLs and PTLs were expressed with LYVE-1 and podoplanin in various tumour tissues, in which initial lymphatics were extremely extended and dilated. The tumour cells were frequently detected adhering to or penetrating lymphatic walls, especially near the open junctions. In the metastatic tissues, lymphangiogenic vasculatures occurred within the tumour matrix, and collecting PTLs represented abnormal twisty valve leaflets. The Western blot and RT-PCR analysis showed local variations of LEC proliferating potentials and lymphatic involvement in metastasis by a distinct profile of the protein and mRNA expression by LYVE-1, podoplanin, Prox-1 and vascular endothelial growth factor-3 (VEGFR-3). These findings indicated that both ITLs and PTLs, including enlarged pre-existing and newly formed lymphatics, may play a crucial role in metastasis with an active tumour cell adhesion, invasion, migration and implantation.
authors: Department of Anatomy, Biology and Medicine, Oita University Faculty of Medicine, Oita, Japan. ji@med.oita-u.ac.jp
authors: R C
authors: RC
authors: Ji
authors: Y
authors: Y
authors: Eshita
authors: S
authors: S
authors: Kato
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D004729:Endothelium, Lymphatic / Q000378:metabolism / Q000473:pathology; D006023:Glycoproteins / Q000378:metabolism*; D018398:Homeodomain Proteins / Q000378:metabolism; D042583:Lymphangiogenesis; D042601:Lymphatic Vessels / Q000378:metabolism / Q000473:pathology* / Q000648:ultrastructure; D008562:Membrane Glycoproteins / Q000378:metabolism*; D026901:Membrane Transport Proteins; D051379:Mice; D008807:Mice, Inbred BALB C; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000378:metabolism*; D009374:Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology* / Q000648:ultrastructure; D025521:Tumor Suppressor Proteins / Q000378:metabolism; D040321:Vascular Endothelial Growth Factor Receptor-3 / Q000378:metabolism; D000098551:Prospero-Related Homeobox 1 Protein; D000098853:Podoplanin
chemical_list: D015415:Biomarkers; D006023:Glycoproteins; D018398:Homeodomain Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009363:Neoplasm Proteins; D025521:Tumor Suppressor Proteins; D040321:Vascular Endothelial Growth Factor Receptor-3; D000098551:Prospero-Related Homeobox 1 Protein; C490441:Pdpn protein, mouse; D000098853:Podoplanin; C492273:LYVE1 protein, mouse
references: EMBO J. 2001 Feb 15;20(4):672-82
references: 11179212
references: Cancer Metastasis Rev. 2006 Dec;25(4):677-94
references: 17160713
references: Nat Med. 2001 Feb;7(2):192-8
references: 11175850
references: Nature. 2001 Mar 1;410(6824):50-6
references: 11242036
references: EMBO J. 2001 Mar 15;20(6):1223-31
references: 11250889
references: Cancer Res. 2001 Nov 15;61(22):8079-84
references: 11719431
references: Cancer Res. 2002 Mar 1;62(5):1315-20
references: 11888898
references: J Natl Cancer Inst. 2002 Mar 20;94(6):417-21
references: 11904313
references: Mod Pathol. 2002 Apr;15(4):434-40
references: 11950918
references: Science. 2002 Jun 7;296(5574):1883-6
references: 11976409
references: Cancer Cell. 2002 Apr;1(3):219-27
references: 12086857
references: Mech Dev. 2002 Oct;118(1-2):147-55
references: 12351178
references: J Exp Med. 2002 Dec 2;196(11):1497-506
references: 12461084
references: Clin Cancer Res. 2003 Jan;9(1):250-6
references: 12538477
references: J Pathol. 2003 Jun;200(2):195-206
references: 12754740
references: Am J Pathol. 2003 Jun;162(6):1951-60
references: 12759251
references: Lab Invest. 2003 Nov;83(11):1681-3
references: 14615421
references: Cancer Res. 2003 Dec 1;63(23):8221-5
references: 14678978
references: Eur J Cancer. 2004 Feb;40(3):358-64
references: 14746853
references: Kidney Int. 2004 Jul;66(1):91-101
references: 15200416
references: Cancer Res. 2004 Jul 1;64(13):4400-4
references: 15231646
references: Br J Cancer. 1996 Dec;74(12):2003-7
references: 8980404
references: Science. 1997 May 30;276(5317):1423-5
references: 9162011
references: Cancer Res. 1998 Apr 15;58(8):1599-604
references: 9563467
references: Exp Cell Res. 1999 Feb 1;246(2):368-75
references: 9925752
references: Am J Pathol. 1999 Feb;154(2):385-94
references: 10027397
references: Histol Histopathol. 2005 Jan;20(1):155-75
references: 15578435
references: Cancer Cell. 2005 Feb;7(2):121-7
references: 15710325
references: Hum Pathol. 2005 Apr;36(4):372-80
references: 15891998
references: Blood. 2005 Jun 15;105(12):4649-56
references: 15705793
references: Acta Neuropathol. 2005 May;109(5):497-502
references: 15864611
references: Cancer Res. 2005 Oct 15;65(20):9261-8
references: 16230387
references: Nature. 2005 Dec 15;438(7070):946-53
references: 16355212
references: Lymphat Res Biol. 2006;4(2):83-100
references: 16808670
references: Anat Sci Int. 2006 Dec;81(4):201-9
references: 17176958
references: Nat Med. 2001 Feb;7(2):186-91
references: 11175849